215 related articles for article (PubMed ID: 14575842)
1. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us?
Wang JZ; Li XA; Yu CX; DiBiase SJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1101-8. PubMed ID: 14575842
[TBL] [Abstract][Full Text] [Related]
2. How low is the alpha/beta ratio for prostate cancer?
Wang JZ; Guerrero M; Li XA
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):194-203. PubMed ID: 12504054
[TBL] [Abstract][Full Text] [Related]
3. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
4. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
5. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy.
Wang JZ; Mayr NA; Nag S; Montebello J; Gupta N; Samsami N; Kanellitsas C
Med Phys; 2006 Apr; 33(4):1025-32. PubMed ID: 16696479
[TBL] [Abstract][Full Text] [Related]
6. Analysis of a large number of clinical studies for breast cancer radiotherapy: estimation of radiobiological parameters for treatment planning.
Guerrero M; Li XA
Phys Med Biol; 2003 Oct; 48(20):3307-26. PubMed ID: 14620060
[TBL] [Abstract][Full Text] [Related]
7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose.
Wang JZ; Li XA
Med Phys; 2003 Jan; 30(1):34-40. PubMed ID: 12557976
[TBL] [Abstract][Full Text] [Related]
9. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.
Brenner DJ; Martinez AA; Edmundson GK; Mitchell C; Thames HD; Armour EP
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):6-13. PubMed ID: 11777617
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
[TBL] [Abstract][Full Text] [Related]
11. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
[TBL] [Abstract][Full Text] [Related]
12. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
13. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
14. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
15. How low is the alpha/beta ratio for prostate cancer?
Kal HB; Van Gellekom MP
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1116-21. PubMed ID: 14575844
[TBL] [Abstract][Full Text] [Related]
16. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of incomplete repair parameters for rat spinal cord: the feasibility of large doses per fraction in PDR and HDR brachytherapy.
Pop LA; Millar WT; Visser AG; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):215-26. PubMed ID: 11516872
[TBL] [Abstract][Full Text] [Related]
18. Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT).
Wang JZ; Li XA; D'Souza WD; Stewart RD
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):543-52. PubMed ID: 12957268
[TBL] [Abstract][Full Text] [Related]
19. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
[TBL] [Abstract][Full Text] [Related]
20. Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?
Morton GC; Hoskin PJ
Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):474-82. PubMed ID: 23727431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
